Results 31 to 40 of about 62,343 (221)

A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice. [PDF]

PLoS Neglected Tropical Diseases, 2015
BACKGROUND:Vibrio cholerae is the cause of cholera, a severe watery diarrhea. Protection against cholera is serogroup specific. Serogroup specificity is defined by the O-specific polysaccharide (OSP) component of lipopolysaccharide (LPS).
Md Abu Sayeed, Meagan Kelly Bufano, Peng Xu, Grace Eckhoff, Richelle C Charles, Mohammad Murshid Alam, Tania Sultana, Md Rasheduzzaman Rashu, Amanda Berger, Geoffrey Gonzalez-Escobedo, Anjali Mandlik, Taufiqur Rahman Bhuiyan, Daniel T Leung, Regina C LaRocque, Jason B Harris, Stephen B Calderwood, Firdausi Qadri, W F Vann, Pavol Kováč, Edward T Ryan   +19 more
doaj   +1 more source

Progress towards meningitis prevention in the conjugate vaccines era

Brazilian Journal of Infectious Diseases
Acute bacterial meningitis is an important cause of morbidity and mortality among children less than five years old. Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis are the most important agents of bacterial meningitis in ...
Cristina Aparecida Borges Laval, Fabiana Cristina Pimenta, João Guimarães de Andrade, Soraya S. Andrade, Ana Lucia S. S. de Andrade   +4 more
doaj   +1 more source

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

Human Vaccines & Immunotherapeutics, 2018
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global ...
A. W. Dretler, N. G. Rouphael, D. S. Stephens   +2 more
doaj   +1 more source

Adesão às novas vacinas conjugadas. Vacina anti-meningocócica e anti-pneumocócica.

Acta Médica Portuguesa, 2004
The new conjugate vaccines against group C meningococcal infection and pneumococcal infection were introduced in Portugal in 2001. In 2001/2002, the media published several alarming news on meningococcal disease and there was an increased demand of those
Laurinda De Queirós, Luis Castro, Maria Carmo Ferreira, Guilherme Gonçalves   +3 more
doaj   +1 more source

Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia. [PDF]

PLoS Medicine, 2005
Pneumonia remains the leading cause of death in young children. The poor specificity of chest radiographs (CXRs) to diagnose pneumococcal pneumonia may underestimate the efficacy of pneumococcal conjugate vaccine in preventing pneumococcal pneumonia.The ...
Shabir A Madhi, Jayvant R Heera, Locadiah Kuwanda, Keith P Klugman   +3 more
doaj   +1 more source

Conjugate vaccines

Expert Review of Vaccines, 2003
Conjugate vaccines in which the capsular polysaccharide of Haemophilus influenzae type b, common serotypes of Streptococcus pneumoniae and group C Neisseria meningitidis are covalently bound to a protein antigen to convert a T-cell-independent immune response into a T-cell-dependent response have proved highly effective in the prevention of invasive ...
openaire   +2 more sources

Evolution of conjugate vaccines

Expert Review of Vaccines, 2002
Conjugate vaccines--bacterial polysaccharides conjugated to proteins to improve their immunizing properties--have been a success story since their introduction less than 20 years ago. The Haemophilus influenzae type b conjugate vaccine has nearly eliminated invasive Haemophilus influenzae type b disease in large parts of the world.
P. Helena Mäkelä, Helena Käyhty
openaire   +3 more sources

Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease among children under five years of age in Africa: A systematic review.

PLoS ONE, 2019
BackgroundDespite the widespread implementation of the pneumococcal conjugate vaccine, Streptococcus pneumoniae remains the leading cause of severe pneumonia associated with mortality among children less than 5 years of age worldwide, with the highest ...
James Samwel Ngocho, Best Magoma, Gaudencia Alois Olomi, Michael Johnson Mahande, Sia Emmanueli Msuya, Marien Isaäk de Jonge, Blandina Theophil Mmbaga   +6 more
doaj   +1 more source

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Emerging Infectious Diseases, 2015
Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1,
Mirjam J. Knol, Gertjan H.J. Wagenvoort, Elisabeth A.M. Sanders, Karin Elberse, Bart J. Vlaminckx, Hester E. de Melker, Arie van der Ende   +6 more
doaj   +1 more source

The Ongoing Journey of a Shigella Bioconjugate Vaccine

Vaccines, 2022
Shigellosis is a serious disease with a major impact, especially in low-income countries where mortality and morbidity are high. In addition, shigellosis among travelers and military personnel is a cause of significant morbidity and contributes to the ...
Patricia Martin, Cristina Alaimo
doaj   +1 more source